202 related articles for article (PubMed ID: 37302352)
21. Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study.
Seman ZA; Ahid F; Kamaluddin NR; Sahid ENM; Esa E; Said SSM; Azman N; Mat WKDW; Abdullah J; Ali NA; Khalid MKNM; Yusoff YM
BMC Res Notes; 2024 Apr; 17(1):111. PubMed ID: 38643202
[TBL] [Abstract][Full Text] [Related]
22. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
23.
Pagani IS; Dang P; Kommers IO; Goyne JM; Nicola M; Saunders VA; Braley J; White DL; Yeung DT; Branford S; Hughes TP; Ross DM
Haematologica; 2018 Dec; 103(12):2026-2032. PubMed ID: 29976745
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
[TBL] [Abstract][Full Text] [Related]
25. Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
Pagnano KBB; Miranda EC; Delamain MT; Duarte GO; de Paula EV; Lorand-Metze I; de Souza CA
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):728-733. PubMed ID: 28822797
[TBL] [Abstract][Full Text] [Related]
26. Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib.
Rostami G; Hamid M; Yaran M; Khani M; Karimipoor M
J Hum Genet; 2015 May; 60(5):253-8. PubMed ID: 25740611
[TBL] [Abstract][Full Text] [Related]
27. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
Hanfstein B; Lauseker M; Hehlmann R; Saussele S; Erben P; Dietz C; Fabarius A; Proetel U; Schnittger S; Haferlach C; Krause SW; Schubert J; Einsele H; Hänel M; Dengler J; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Pfirrmann M; Hasford J; Hofmann WK; Hochhaus A; Müller MC;
Haematologica; 2014 Sep; 99(9):1441-7. PubMed ID: 24837466
[TBL] [Abstract][Full Text] [Related]
28. [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
Cayuela JM; Chomel JC; Coiteux V; Dulucq S; Escoffre-Barbe M; Etancelin P; Etienne G; Hayette S; Millot F; Nibourel O; Nicolini FE; Réa D;
Bull Cancer; 2020 Jan; 107(1):113-128. PubMed ID: 31353136
[TBL] [Abstract][Full Text] [Related]
29. Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia.
Tadesse F; Asres G; Abubeker A; Gebremedhin A; Radich J
JCO Glob Oncol; 2021 Jul; 7():1187-1193. PubMed ID: 34292760
[TBL] [Abstract][Full Text] [Related]
30. Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
Vatanmakanian M; Tavallaie M; Ghadami S
Cell Commun Signal; 2019 Apr; 17(1):38. PubMed ID: 31014357
[TBL] [Abstract][Full Text] [Related]
31. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
Aranda-Tavío H; Recio C; Martín-Acosta P; Guerra-Rodríguez M; Brito-Casillas Y; Blanco R; Junco V; León J; Montero JC; Gandullo-Sánchez L; McNaughton-Smith G; Zapata JM; Pandiella A; Amesty A; Estévez-Braun A; Fernández-Pérez L; Guerra B
Biomed Pharmacother; 2021 Dec; 144():112330. PubMed ID: 34673425
[TBL] [Abstract][Full Text] [Related]
32. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
McCarron SL; Langabeer SE; Bolger K; Haslam K; Crampe M; Kelly J; Morrell R
Med Oncol; 2015 Feb; 32(2):452. PubMed ID: 25579165
[TBL] [Abstract][Full Text] [Related]
33. No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.
Pfirrmann M; Evtimova D; Saussele S; Castagnetti F; Cervantes F; Janssen J; Hoffmann VS; Gugliotta G; Hehlmann R; Hochhaus A; Hasford J; Baccarani M
J Cancer Res Clin Oncol; 2017 May; 143(5):843-850. PubMed ID: 28083711
[TBL] [Abstract][Full Text] [Related]
34. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
Khorashad JS; Kelley TW; Szankasi P; Mason CC; Soverini S; Adrian LT; Eide CA; Zabriskie MS; Lange T; Estrada JC; Pomicter AD; Eiring AM; Kraft IL; Anderson DJ; Gu Z; Alikian M; Reid AG; Foroni L; Marin D; Druker BJ; O'Hare T; Deininger MW
Blood; 2013 Jan; 121(3):489-98. PubMed ID: 23223358
[TBL] [Abstract][Full Text] [Related]
35. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
[No Abstract] [Full Text] [Related]
36. E255K and G250E mutation appearing in a patient with e19a2 chronic myeloid leukemia resistant to imatinib.
Li C; Wang Y; Xu D; Zhang P; Ding X; Zhang N; Xiao M; Huang L; Meng L
Clin Lab; 2015; 61(1-2):183-6. PubMed ID: 25807654
[TBL] [Abstract][Full Text] [Related]
37. [Chronic myeloid leukemia with variant e13a3 (b2a3) BCR-ABL1 as an ABL1 tyrosine kinase inhibitor-sensitive subtype].
Togitani K; Asagiri T; Kamioka M; Kojima K
Rinsho Ketsueki; 2021; 62(3):180-185. PubMed ID: 33828011
[TBL] [Abstract][Full Text] [Related]
38. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Stella S; Zammit V; Vitale SR; Pennisi MS; Massimino M; Tirrò E; Forte S; Spitaleri A; Antolino A; Siracusa S; Accurso V; Mannina D; Impera S; Musolino C; Russo S; Malato A; Mineo G; Musso M; Porretto F; Martino B; Di Raimondo F; Manzella L; Vigneri P; Stagno F
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064152
[TBL] [Abstract][Full Text] [Related]
39. Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.
Soverini S; De Santis S; Martelli M; Monaldi C; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Bruno S; Venturi C; Machova Polakova K; Ernst T; Maar D; Corner A; Cavo M
Leukemia; 2022 Sep; 36(9):2250-2260. PubMed ID: 35908105
[TBL] [Abstract][Full Text] [Related]
40. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Bandyopadhyay S; Li J; Traer E; Tyner JW; Zhou A; Oh ST; Cheng JX
PLoS One; 2017; 12(7):e0179558. PubMed ID: 28719608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]